Treatment of inflammatory lung disease by combined inhibition of il-33 and il-6 with bispecific antibodies

WO2026131910A1PCT designated stage Publication Date: 2026-06-25F HOFFMANN LA ROCHE & CO AG +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
F HOFFMANN LA ROCHE & CO AG
Filing Date
2025-12-17
Publication Date
2026-06-25

Smart Images

  • Figure EP2025087503_25062026_PF_FP_ABST
    Figure EP2025087503_25062026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention generally relates to the treatment of chronic obstructive pulmonary disease (CORD), and to therapeutic agents useful therefor. In particular, the present invention relates to antibodies, including bispecific antibodies inhibiting IL-33 and IL-6, useful for the treatment of inflammatory lung disease. In addition, the invention relates to polynucleotides encoding such antibodies, vectors and host cells comprising such polynucleotides, as well as methods for producing such antibodies.
Need to check novelty before this filing date? Find Prior Art